Merck & Co. Inc. (NYSE:MRK) was a drag on the Dow Jones Industrial Common on Feb. five. Although the DJIA soared extra than 483 details, Merck shares slumped $two.53 to $85.eighty three. It appears the drop was tied to the company’s prolonged anticipated announcement that it was spinning off its women’s health and biosimilars organizations as well as lessen-than-expected fourth-quarter sales, like a moderate profits disappointment for its crucial drug.
Total fourth-quarter profits rose 8% to just below $twelve billion, just lacking anticipations. In the course of the ultimate 3 months of 2019, sales of Merck’s blockbuster most cancers drug